Professor Ian McAllister has a doctorate in medicine and is actively involved in research for cures for vitreoretinal disorders, particularly retinal vascular disorders. He has held 10 NHMRC grants in this area as well as numerous minor grants. Professor McAllister undertook training in Western Australia with additional sub-specialty training in vitreoretinal disorders at the Cleveland Clinic in the USA for two years.
He is a consultant ophthalmologist at the Lions Eye Institute. He was a consultant ophthalmologist at Royal Perth Hospital for 32 years and a previous head of the department. He has been involved for many years in state-wide diabetic retinopathy screening and treatment and was vice-chairman of the Ophthalmic Research Institute of Australia and chairman of the Research Board for many years. He has published more than 160 papers in scientific journals and has given over 180 papers at national and international meetings as an invited guest speaker.
Education/academic qualifications/roles responsibilities
- MBBS
- FRACS
- FRANZCO
- DM
- Professor of Ophthalmology, The University of Western Australia
- Consultant Ophthalmologist at the Royal Perth and Sir Charles Gairdner Hospitals
- More than 180 presentations as an invited speaker at national and international conferences
Awards/professional achievements
- 2019 Member Retina Hall of Fame
- 2012 American Academy of Ophthalmology Achievement award for distinguished service to ophthalmology.
- 1995 Pharmacia Award – For best scientific paper at the 27th Annual Congress of the Royal Australian College of Ophthalmologists.
- Grants/scholarships/funding overview
- Held 10 NHMRC grants in cures for vitreoretinal disorders
- Held six Ophthalmic Research Institute of Australia research grants
Publications
- Published more than 160 referee reviewed papers on eye disorders in scientific journals
Research Activity
- Retinal vascular disorders: Cytokine up regulation and neuroprotection. Innovative new treatment options.
- Macular degeneration: Natural history and therapeutic options.
- Clinical trials for macular oedema, diabetic retinopathy, retinal vascular diseases and macular degeneration.
